Literature DB >> 9150407

Three-dimensional structure of an Fab-peptide complex: structural basis of HIV-1 protease inhibition by a monoclonal antibody.

J Lescar1, R Stouracova, M M Riottot, V Chitarra, J Brynda, M Fabry, M Horejsi, J Sedlacek, G A Bentley.   

Abstract

F11.2.32, a monoclonal antibody raised against HIV-1 protease (Kd = 5 nM), which inhibits proteolytic activity of the enzyme (K(inh) = 35(+/-3)nM), has been studied by crystallographic methods. The three-dimensional structure of the complex between the Fab fragment and a synthetic peptide, spanning residues 36 to 46 of the protease, has been determined at 2.2 A resolution, and that of the Fab in the free state has been determined at 2.6 A resolution. The refined model of the complex reveals ten well-ordered residues of the peptide (P36 to P45) bound in a hydrophobic cavity at the centre of the antigen-binding site. The peptide adopts a beta hairpin-like structure in which residues P38 to P42 form a type II beta-turn conformation. An intermolecular antiparallel beta-sheet is formed between the peptide and the CDR3-H loop of the antibody; additional polar interactions occur between main-chain atoms of the peptide and hydroxyl groups from tyrosine residues protruding from CDR1-L and CDR3-H. Three water molecules, located at the antigen-antibody interface, mediate polar interactions between the peptide and the most buried hypervariable loops, CDR3-L and CDR1-H. A comparison between the free and complexed Fab fragments shows that significant conformational changes occur in the long hypervariable regions, CDR1-L and CDR3-H, upon binding the peptide. The conformation of the bound peptide, which shows no overall structural similarity to the corresponding segment in HIV-1 protease, suggests that F11.2.32 might inhibit proteolysis by distorting the native structure of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150407     DOI: 10.1006/jmbi.1997.0950

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  12 in total

1.  Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.

Authors:  J Lescar; J Brynda; P Rezacova; R Stouracova; M M Riottot; V Chitarra; M Fabry; M Horejsi; J Sedlacek; G A Bentley
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

2.  An insight into the thermodynamic characteristics of human thrombopoietin complexation with TN1 antibody.

Authors:  Shigeki Arai; Chie Shibazaki; Motoyasu Adachi; Eijiro Honjo; Taro Tamada; Yoshitake Maeda; Tomoyuki Tahara; Takashi Kato; Hiroshi Miyazaki; Michael Blaber; Ryota Kuroki
Journal:  Protein Sci       Date:  2016-07-25       Impact factor: 6.725

3.  Cloning and sequence analysis of cDNAs encoding the heavy and light chain variable regions of an Ab2beta anti-idiotypic monoclonal antibody possessing an internal image of cocaine.

Authors:  M Ho; M Segre
Journal:  Biochim Biophys Acta       Date:  2001-10-31

4.  Prediction of the interacting surfaces in a trimolecular complex formed between the major dust mite allergen Der p 1, a mouse monoclonal anti-Der p 1 antibody, and its anti-idiotype.

Authors:  P B Furtado; R Furmonaviciene; J McElveen; H F Sewell; F Shakib
Journal:  Mol Pathol       Date:  2000-12

5.  A beta -hairpin structure in a 13-mer peptide that binds alpha -bungarotoxin with high affinity and neutralizes its toxicity.

Authors:  T Scherf; R Kasher; M Balass; M Fridkin; S Fuchs; E Katchalski-Katzir
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

6.  Mechanism of dissociative inhibition of HIV protease and its autoprocessing from a precursor.

Authors:  Jane M Sayer; Annie Aniana; John M Louis
Journal:  J Mol Biol       Date:  2012-05-30       Impact factor: 5.469

7.  Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.

Authors:  Chunxia Qiao; Meiyun Hu; Leiming Guo; Ming Lv; Zhou Lin; Jing Geng; Xiaoling Lang; Xinying Li; Yan Li; Yuanfang Ma; Jiannan Feng; Beifen Shen
Journal:  BMC Immunol       Date:  2012-07-12       Impact factor: 3.615

8.  Current and Novel Inhibitors of HIV Protease.

Authors:  Jana Pokorná; Ladislav Machala; Pavlína Rezáčová; Jan Konvalinka
Journal:  Viruses       Date:  2009-12-11       Impact factor: 5.048

9.  Antibody Binding Selectivity: Alternative Sets of Antigen Residues Entail High-Affinity Recognition.

Authors:  Yves Nominé; Laurence Choulier; Gilles Travé; Thierry Vernet; Danièle Altschuh
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

10.  An apoptosis-associated mammary protein deficiency leads to enhanced production of IgM antibodies against multiple damage-associated molecules.

Authors:  Miho Chikazawa; Natsuki Otaki; Takahiro Shibata; Takehiko Yasueda; Tsukasa Matsuda; Koji Uchida
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.